Surgical Site Infection Control Market Size

Surgical Site Infection (SSI) Control Market Analysis

The Surgical Site Infection Control Market size is estimated at USD 5.35 billion in 2024, and is expected to reach USD 6.45 billion by 2029, growing at a CAGR of 3.80% during the forecast period (2024-2029).

COVID-19 had an impact on surgical operations performed globally. Due to regulatory authorities' strict guidance to prevent any non-emergent surgeries, the volume of surgeries drastically decreased throughout the pandemic. For instance, according to the study published in October 2021 by the National Library of Medicine, there was a 42.8% decrease in general surgery admissions globally. As a result, the COVID-19 pandemic substantially impacted the surgical site infection control market. However, the COVID-19 pandemic underlined the critical necessity of hand hygiene and the use of conventional infection control methods. Moreover, owing to the resumption of elective surgeries and stabilizing COVID-19 cases, the market soon bolstered to its pre-pandemic levels. For instance, in March 2022, PDI launched Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe, and Sani-HyPerCide Germicidal Spray, innovative disinfectants to help infection prevention professionals in the fight against rising healthcare-associated infections (HAIs) as well as the ongoing battle against COVID-19.

The increasing number of hospital-acquired infections is due to the rising total number of surgeries and the growing geriatric population. According to an article published in April 2022 by UpToDate, surgical site infection (SSI) is the most common healthcare-associated infection following surgery. It is associated with significant morbidity and mortality, transfer to an intensive care unit setting, prolonged hospitalizations, and hospital readmission. Among those who undergo surgical procedures annually in the United States, 2 to 45 will develop an SSI, representing a significant burden on the health care system. Such a high burden of surgical site infection is expected to drive the market's growth.

Furthermore, according to the United Nations' World Ageing Population 2022 highlights, The share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. By 2050, the number of persons aged 65 years or over worldwide is projected to be more than twice the number of children under 5 years and about the same that of children under 12 years. Thus, with the growing age, people are more prone to several chronic diseases and need surgical measures, which are expected to boost the growth of the surgical site infection control market over the forecast period. Moreover, as per the data published by the Health Resources and Services Administration in March 2022, about 40,000 organ transplants were performed in the United States in 2021. In addition, 26,670 kidney transplants and 9,236 live transplants were performed in 2021 in the United States. Therefore, the increased organ transplant is expected to increase surgical site infections and increase the demand for the control of such infections. The market is expected to see a surge over the forecast period.

Additionally, technological advancements, and an increase in the number of surgical site infections during surgical procedures, further drive the growth of the market studied. For instance, in March 2022, TELA Bio launched SiteGuard, a no-rinse antimicrobial solution. SiteGuard utilizes Next Science's proprietary XBIO Technology that supports surgical site and post-operative infection control by addressing the biofilms that make bacteria more resistant to traditional antimicrobial agents, disinfectants, and host immune defenses.

However, a lack of awareness about SSI among individuals restrained the market over the forecast period.